BALAGLITAZONE

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H17N3O4S
Molecular Weight	395.432
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CN1C(=O)C2=C(C=CC=C2)N=C1COC3=CC=C(CC4SC(=O)NC4=O)C=C3

InChI

InChIKey=IETKPTYAGKZLKY-UHFFFAOYSA-N

InChI=1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,16H,10-11H2,1H3,(H,22,24,26)

HIDE SMILES / InChI

Molecular Formula	C20H17N3O4S
Molecular Weight	395.432
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description

Balaglitazone is a second generation peroxisome proliferator-activated receptor (PPAR) gamma agonist with only partial agonistic properties. It passed phase III clinical trial for the treatment of type 2 diabetes. However, Dr. Reddy's Laboratories decided to terminate further clinical development of balaglitazone.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor gamma 111	Partial Agonist 290

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 259	Primary		Phase III 656	BALAGLITAZONE

Doses

Show entries

Dose	Population	Adverse events
10 mg 1 times / day multiple, oral (unknown) Studied dose	unhealthy, ADULT n = 97	Disc. AE: sinusitis, oedemas...
20 mg 1 times / day multiple, oral (unknown) Studied dose	unhealthy, ADULT n = 97	Disc. AE: fatigue, Deep vein thrombosis...

Showing 1 to 2 of 2 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
oedemas	1 pt Disc. AE	10 mg 1 times / day multiple, oral (unknown) Studied dose	unhealthy, ADULT n = 97
Deep vein thrombosis	2 patients Disc. AE	10 mg 1 times / day multiple, oral (unknown) Studied dose	unhealthy, ADULT n = 97
Fatigue	2 patients Disc. AE	10 mg 1 times / day multiple, oral (unknown) Studied dose	unhealthy, ADULT n = 97
sinusitis	2 patients Disc. AE	10 mg 1 times / day multiple, oral (unknown) Studied dose	unhealthy, ADULT n = 97
weight increases	2 patients Disc. AE	10 mg 1 times / day multiple, oral (unknown) Studied dose	unhealthy, ADULT n = 97

Showing 1 to 5 of 10 entries

Previous1 2Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as perpetrator

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1,650	supressor 155	yes

Showing 1 to 1 of 1 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
001 Chemical	DY537317	https://www.001chemical.com/chem/199113-98-9
AA Blocks	AA002BTS	https://www.aablocks.com/goods/Goods/detail?id=AA002BTS
Aaron Chemicals	AR002CLK	http://www.aaronchem.com/199113-98-9
AbMole Bioscience	M9496	http://www.abmole.com/products/balaglitazone.html
Achemtek	0102-014237	http://www.achemtek.com/199113-98-9

Showing 1 to 5 of 33 entries

Previous1 2 3 4 5 6 7Next

PubMed

Show entries

Title	Date	PubMed
Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist.	2012 Feb	22372600

Showing 1 to 1 of 1 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

One arm balaglitazone 10 mg, one arm balaglitazone 20 mg, orally taken once daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical
Record UNII	4M1609828O
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

BALAGLITAZONE

Official Name

English

5-((4-((3-METHYL-4-OXO-3,4-DIHYDRO-2-QUINAZOLINYL)METHOXY)PHENYL)METHYL)THIAZOLIDINE-2,4-DIONE

Systematic Name

English

(±)-5-(P-((3,4-DIHYDRO-3-METHYL-4-OXO-2-QUINAZOLINYL)METHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE

Common Name

English

2,4-THIAZOLIDINEDIONE, 5-((4-((3,4-DIHYDRO-3-METHYL-4-OXO-2-QUINAZOLINYL)METHOXY)PHENYL)METHYL)-

Systematic Name

English

Balaglitazone [WHO-DD]

Common Name

English

Showing 1 to 5 of 8 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

Anti-diabetic Agent

NCI_THESAURUS

C98241

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

ChEMBL

CHEMBL2103991

PRIMARY

EVMPD

SUB25428

PRIMARY

CAS

199113-98-9

PRIMARY

NCI_THESAURUS

C78125

PRIMARY

FDA UNII

4M1609828O

PRIMARY

Showing 1 to 5 of 11 entries

Previous1 2 3Next

Show entries

Related Record

Type

Details


					2U9J272649

BALAGLITAZONE, (R)-

ENANTIOMER -> RACEMATE

Amount:


					KPK1FF8WC4

BALAGLITAZONE, (S)-

ENANTIOMER -> RACEMATE

Amount:


					AL17N8ZSWL

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA

TARGET->PARTIAL AGONIST

Amount:

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Related Record

Type

Details


					4M1609828O

BALAGLITAZONE

ACTIVE MOIETY

Amount:

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Sourcing

PubMed

Patents

Sample Use Guides

Drug as perpetrator